NCT01075321 2020-10-22Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaMayo ClinicPhase 1/2 Completed58 enrolled 12 charts
NCT00918333 2020-03-10Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaMayo ClinicPhase 1/2 Completed124 enrolled 10 charts
NCT00436618 2019-10-22Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentMayo ClinicPhase 2 Completed277 enrolled 11 charts
NCT00474929 2019-08-20Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMayo ClinicPhase 1/2 Completed103 enrolled 12 charts
NCT02240719 2019-01-04Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerUniversity of California, DavisPhase 1 Completed20 enrolled
NCT01334502 2017-08-10Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaAlliance for Clinical Trials in OncologyPhase 1 Completed26 enrolled
NCT00352443 2015-03-06S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaSWOG Cancer Research NetworkPhase 1 Completed66 enrolled
NCT00869999 2014-10-27Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaMassachusetts General HospitalPhase 2 Completed26 enrolled 8 charts
NCT00962507 2013-02-15Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCity of Hope Medical CenterPhase 1 Completed11 enrolled